Personalized prognosis in unresectable hepatocellular carcinoma: Development and validation of a model for transcatheter arterial chemoembolization plus lenvatinib
Models based on nine variables from 43 group studies predicted the efficacy of TACE plus lenvatinib in unresectable HCC, supporting evidence-based clinical decisions and treatment strategies.
Authors
- Jun Yu
- Jianchun Xian (ORCID: https://orcid.org/0000-0003-0671-8489)
- Junsheng Yu (ORCID: https://orcid.org/0000-0002-7484-8114)
- Yan Duan (ORCID: https://orcid.org/0000-0002-1100-6729)
- Yi Liu (ORCID: https://orcid.org/0000-0001-6180-8175)
- Jiahui Yu (ORCID: https://orcid.org/0000-0003-4329-2739)
- Linfeng Yang
- Pengsheng Yi
Institutions
- North Sichuan Medical University (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2025-11-12
- DOI
- https://doi.org/10.4251/wjgo.v17.i11.111814
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00